Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...
Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study
Swiss pharmaceutical major Novartis (NYSE: NVS) has released positive topline results from the APPULSE-PNH Phase...
Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion
China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a...
Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion
The acquisition of contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) by Novo Holdings...
Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024
US healthcare conglomerate Johnson & Johnson (J&J, NYSE: JNJ) has presented results from several clinical...
AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC
UK-based pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN) has announced positive results from the PACIFIC-5 III...
Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Innovent Biologics’ IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia
China-based biopharmaceutical company Innovent Biologics, Inc. (HKG: 1801) presented updated data from the Phase I...
Hainan Haiyao Secures Exclusive Rights for AFT Pharmaceuticals’ Nutritional Products in China
China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced a significant licensing agreement with Australia-based...
Novartis’ Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) unveiled longer-term results from the pivotal Phase III ASC4FIRST...
Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...
Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation
US pharmaceutical giant Merck (NYSE: MRK) has revealed promising data from the Phase II waveLINE-007...
Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange
Medtide Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides and based...
AstraZeneca’s Calquence Combo Shows 35% Reduced Risk in CLL: AMPLIFY Phase III Results
At the 66th American Society of Hematology (ASH) annual meeting, UK pharmaceutical major AstraZeneca (AZ,...
Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...
Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study
Jacobio Pharma (HKG: 1167) has announced the presentation of preliminary results from the Phase I...
Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from...
Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the...
Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced
China-based innovative drug company Chipscreen Biosciences (SHA: 688321) has announced the completion of the analysis...